Table 3.
Comparison of survived versus deceased patients with metformin-associated lactic acidosis
| All patients with MALA (n = 10) | Survived (n = 5) | Deceased (n = 5) | |
|---|---|---|---|
| Age, years | 66 ± 9 | 64 ± 5 | 69 ± 11 |
| Male gender | 4 (40%) | 3 (60%) | 1 (20%) |
| SAPS II | 88 ± 23 | 73 ± 25 | 103 ± 7 |
| SOFA score | 14.3 ± 1.4 | 13.8 ± 1.5 | 14.8 ± 1.3 |
| Respiratory | 2.7 ± 0.9 | 2.4 ± 1.1 | 3.0 ± 0.7 |
| Renal | 4.0 ± 0.0 | 4.0 ± 0.0 | 4.0 ± 0.0 |
| Hepatic | 0.3 ± 0.7 | 0.4 ± 0.9 | 0.2 ± 0.4 |
| Cardiovascular | 4.0 ± 0.0 | 4.0 ± 0.0 | 4.0 ± 0.0 |
| Hematologic | 0.5 ± 0.8 | 0.4 ± 0.9 | 0.6 ± 0.9 |
| Neurologic | 2.8 ± 1.5 | 2.6 ± 1.3 | 3.0 ± 1.7 |
| Lactate, mmol/L | 18.7 ± 5.3 | 17.7 ± 5.3 | 19.8 ± 5.7 |
| pH | 6.75 ± 0.13 | 6.72 ± 0.17 | 6.77 ± 0.07 |
| Prothrombin activity, % | 69.1 ± 27.7a | 78.0 ± 24.6 | 58.0 ± 30.7a |
| Serum metformin, mg/L | 55 ± 13 | 52 ± 7 | 58 ± 19 |
Values other than 'Male gender', which is presented as number (percentage), are presented as mean ± standard deviation. aOne patient was omitted with 11% prothrombin activity due to cumarin therapy. MALA, metformin-associated lactic acidosis; SAPS II, Simplified Acute Physiology Score II; SOFA, Sequential Organ Failure Assessment.